Chronic Lymphocytic Leukemia | Clinical

Greater Understanding of CLL Pathophysiology Spurs Small Molecules Development

October 25, 2022

William Wierda, MD, PhD, explored the emergence of small molecule-inhibitor targeted therapies during the “Workup of CLL in the Era of Small Molecules,” presentation at the 10th Annual Meeting of the Society of Hematologic Oncology.

First Patient With B-NHL or CLL Treated With MB-106 in Phase 1/2 Study

October 10, 2022

The phase 1/2 clinical trial of MB-106 is demonstrating high efficacy, durable responses, and a favorable safety profile as the first patient treated did not experience cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome